Efficacy and Safety Study of ALS-L1023 in Patients With Abdominal Obesity of Metabolic Syndrome

A Randomized, Double-Blind, Placebo Controlled, Multicenter, 12-week Phase 3 Study to Evaluate Efficacy and Safety of ALS-L1023 Tablet in Patients With Abdominal Obesity of Metabolic Syndrome

The main objective of this study is to evaluate efficacy and safety of ALS-L1023 tablet in patients with abdominal obesity of metabolic syndrome.

Inclusion Criteria:

• Aged between 20 and 64 years(Both genders)

• more than 2 among components of the metabolic syndrome

  • Triglyceride >= 150mg/dL
  • HDL-D: Women < 50mg/dL or Men < 40mg/dL
  • Hypertension: Systolic blood pressure >= 130mmHg or Diastolic blood pressure >= 85mmHg
  • Hyperglycemia: fasting plasma glucose >= 100 mg/dL

• Informed consent awarding

Exclusion Criteria:

• Alcohol or any drug abuse
• Any investigational medication during the preceding 3 months